Literature DB >> 25721251

Prediction of drug clearance in children.

Frantz Foissac1,2,3, Naïm Bouazza1,2,3, Elodie Valade1,2,3, Mailys De Sousa Mendes1,2,3, Floris Fauchet1,2,3, Sihem Benaboud1,2,3,4, Déborah Hirt1,2,3,4, Jean-Marc Tréluyer1,2,3,4, Saïk Urien1,2,3.   

Abstract

The pediatric population is often exposed to drugs without sufficient knowledge about pharmacokinetics. The prediction of accurate clearance values in children, especially in neonates and infants, will improve the rational in dosing decisions. Drug clearances from birth to adulthood were compiled after a systematic review of pharmacokinetic reports. The analysis was performed using NONMEM. Clearance predictions were then evaluated by external validation. Prediction errors were also compared with those obtained from weight-based allometric scaling and physiologically based clearance (PBCL) models. For the analysis, 17 and 15 drugs were used for model building and external validation, respectively. A model based on the adult drug clearance value and taking into account both weight and age was retained. Age-related maturation of clearance reached 90% of the adult value within 1.5 years of life. For children less than 2 years old, allometric scaling alone systematically overestimated clearances. Accounting for age improved the clearance prediction in the 6 months-2 years age group (prediction error < 25%). Predictions obtained from the PBCL approach were close to our results. This analysis established a single equation using the adult clearance value as well as individual age and weight to predict drug clearance in children older than 6 months.
© 2015, The American College of Clinical Pharmacology.

Entities:  

Keywords:  allometric scaling; clearance; elimination; maturation; pediatric

Mesh:

Substances:

Year:  2015        PMID: 25721251     DOI: 10.1002/jcph.488

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  6 in total

1.  Model-based approaches for ivabradine development in paediatric population, part I: study preparation assessment.

Authors:  Sophie Peigné; François Bouzom; Karl Brendel; Charlotte Gesson; Sylvain Fouliard; Marylore Chenel
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-11-12       Impact factor: 2.745

2.  Pediatric Development of Bosentan Facilitated by Modeling and Simulation.

Authors:  Jochen Zisowsky; Martine Géhin; Andjela Kusic-Pajic; Andreas Krause; Maurice Beghetti; Jasper Dingemanse
Journal:  Paediatr Drugs       Date:  2017-04       Impact factor: 3.022

3.  A General Biphasic Bodyweight Model for Scaling Basal Metabolic Rate, Glomerular Filtration Rate, and Drug Clearance from Birth to Adulthood.

Authors:  Teh-Min Hu
Journal:  AAPS J       Date:  2022-05-10       Impact factor: 3.603

4.  Pharmacokinetics of Dexmedetomidine in Infants and Children After Orthotopic Liver Transplantation.

Authors:  Mihaela A Damian; Gregory B Hammer; Mohammed H Elkomy; Adam Frymoyer; David R Drover; Felice Su
Journal:  Anesth Analg       Date:  2020-01       Impact factor: 5.108

5.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

6.  Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method.

Authors:  E A M Calvier; E H J Krekels; T N Johnson; A Rostami-Hodjegan; D Tibboel; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2019-03-08       Impact factor: 4.009

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.